O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Executive Director Brand Lead - Specialty Psychiatry

Full-TimeUpdated on 10/23/2026
$250k - $388.1k+ Incentive opportunity
Expert
Bachelor's, MBA
Remote in USA
Remote
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree in Business or a related field is required; an MBA is preferred.
  • At least 15 years of pharmaceutical commercial experience, with a strong background in CNS, neurology, psychiatry, or related therapeutic areas and commercial models.
  • Experience with provider and site-of-care account marketing, practice economics and reimbursement, specialty buy-and-bill, operational workflows, and support services for complex high-touch therapeutics is required.
  • Some experience working within a portfolio of related or integrated products in a specific therapeutic area or across indications is desired.
  • Proven leadership in brand and portfolio strategy, launch planning, and lifecycle management, with experience managing assets with multiple indications.
  • Ability to partner with R&D and Medical Affairs to build short- and long-term integrated evidence plans and strategies to address key market needs and opportunities.
  • Experience leading HCP and consumer marketing functions.
  • Experience developing clinical, economic, and operational value propositions for provider accounts and building site-of-care marketing plans is required.
  • Demonstrated ability to lead highly complex brands, including REMS, specialty distribution, buy-and-bill, new healthcare delivery models, and integration into clinical workflows, is required.
  • Strong cross-functional collaboration skills, with experience partnering closely with R&D, Medical, and Global colleagues to build asset differentiation and portfolio strategies.
  • Accountable leader with a growth mindset that drives meaningful change and innovation.
  • Omnichannel marketing expertise, including digital, non-personal promotion, and traditional engagement strategies.
  • High level of demonstrated financial acumen, with experience in budget management and marketing ROI optimization, forecasting, and P&L management.
  • Strong people leadership skills, with experience managing and developing high-performing teams and individuals.
  • Ability to influence and communicate effectively with executive leadership, cross-functional teams, and external stakeholders.
  • Experience working in a matrixed environment, managing multiple priorities and complex brand challenges.
Responsibilities
  • Develop and implement the overall customer engagement model, including cross-functional field roles, support services, distribution models, virtual tools, and external partnerships for TSND-201 and the future specialty portfolio.
  • Lead the commercialization strategy for TSND-201 and ensure a competitive, differentiated market position and strategic alignment of plans across functions.
  • Build future commercial strategies and infrastructure to establish and sustain a leading portfolio of specialty psychiatric assets in partnership with key stakeholders.
  • Collaborate with market access, sales, medical, clinical development, communications, finance, and other functions to develop integrated brand strategies, plans, and key initiatives.
  • Oversee HCP, provider account, and consumer marketing teams to ensure effective multichannel strategies and personalized engagement content that drive engagement, awareness, and adherence.
  • Lead a team of HCP, provider account, and consumer franchise directors and marketers, providing guidance, mentorship, and strategic direction to drive high performance and excellence.
  • Use market research, analytics, and competitive intelligence to build brand strategy and plans, adjust tactics, and stay ahead of evolving industry trends.
  • Ensure HCP marketing initiatives support brand objectives, including field promotion, digital and non-personal promotion, speaker programs, KOL and professional engagement, and congress strategies.
  • Guide consumer-focused strategies so patient and caregiver awareness, education, and engagement align with brand objectives; own direct-to-consumer initiatives and tactics.
  • Build the overall value proposition story for stakeholders across sites of care, IDNs, and provider accounts; ensure delivery frameworks through key account teams integrate TSND-201 into clinical, economic, and financial workflows; partner with outside organizations and customers to ensure sufficient long-term capacity for patient treatment and support.
  • Own P&L planning and responsibility for TSND-201, including net sales forecasts, promotional mix optimization, budget planning, long-term franchise and portfolio valuation, and alignment of investments across functions to brand strategy.
  • Oversee commercialization of TSND-201 to ensure seamless launch execution and long-term growth planning; own the cross-functional launch team and integrated readiness plans across the organization.
  • Lead the strategic direction, performance, and lifecycle management of the pharmaceutical brand portfolio to achieve growth, patient impact, and financial objectives.
  • Drive cross-functional alignment across marketing, sales, medical, market access, and operations to develop integrated business plans and execute them to meet P&L goals.
  • Lead pre- and post-launch commercialization responsibilities and P&L ownership, and help steer the global lifecycle management plan, portfolio strategy, and launch planning for pipeline assets across potential indications.
Desired Qualifications
  • Experience working within a portfolio of related or integrated products in a specific therapeutic area or across indications.
  • Experience in market access, sales, and/or commercial operations is highly preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.